Video recording (click here to watch on YouTube)


The proposed uses of AI in the health sector have elicited reactions from hope to handwringing to hype. In response, governments, NGOs, professional organizations, and the standards community have been busy developing guidelines, frameworks, principles, and other oversight tools with the laudable intention of crafting responsible governance policy for AI in health. Yet with so many players and documents in circulation, it is not surprising that there are gaps, inconsistencies, and contradictions, impeding the very progress such work was meant to enable. This lecture will examine the roots and causes of these impediments, including those in the bioethics and governance communities themselves, and consider what steps might be taken now to ensure that health care can benefit from AI for the right reasons.

About the Speaker:

Dr Eric M. Meslin, PhD, FRSC, FCAHS, ICD.D.

Dr. Eric Meslin has had a 35-year long career spanning clinical, academic, government and not-for-profit settings, a common thread through which has been a focus on ethical, social and policy implications of health, science, and technology. He recently stepped down after eight years as President and CEO.of the Council of Canadian Academies, an organization that undertakes assessments of evidence for the Government of Canada on climate, science and technology, innovation, health care, and energy policy.

Dr. Meslin is currently Senior Fellow of the PHG Foundation, Distinguished Visiting Scholar at University of Miami, Adjunct Professor University Toronto, and Visiting Scholar at Centre of Genomics and Policy McGill University.His academic career includes many “firsts” including establishing Canada’s first comprehensive clinical ethics centre at Sunnybrook Health Science Centre; helping build the University of Toronto Centre for Bioethics (now the Joint Centre for Bioethics); and for 15 years as Founding Director of the Indiana University Center for Bioethics and Indiana’s first Endowed Chair in Bioethics.

Dr. Meslin’s leadership roles included Bioethics Research Director of the Ethical, Legal, and Social Implications (ELSI) program in the early years of the Human Genome Project, and Executive Director of the U.S. National Bioethics Advisory Commission, advising the White House on stem cell science, cloning, international clinical trials, and genomics. Trained in philosophy and bioethics from Georgetown University, he has held many advisory positions including OECD, WHO, ELIXIR, and UNESCO, and published more than 200 articles, book chapters, and two co-edited books. Dr Meslin is a Fellow of the Royal Society of Canada, the Canadian Academy of Health Sciences, and The Hastings Center. He is also a Chevalier de l’Ordre Nationale du Mérite (Knight of the National Order of Merit) for contributions to French bioethics policy.

Event page of the PHG Foundation: click here

  • WYNG-Hatton Lecture
Date & Time
  • 17 Apr, 2024 6:15 pm - 7:30 pm

St Catharine’s College, University of Cambridge, United Kingdom

Skip to content